Evaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis

Min Dai,1,2 Yuxiong Jiang,1,2 Yujing Xi,3 Lezhen Xu,4 Dawei Huang,1,2 Yu Wang,1,5 Yifan Hu,1,5 Qian Yu,1,2,5 Yuling Shi1,2,5 1Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 2Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People’s Republic of China; 3Kashi Prefecture Second People’s Hospital, Kashi, Xinjiang, People’s Republic of China; 4Department of Dermatology, The Third Affliated Hospital of Naval Medical University, Shanghai, People’s Republic of China; 5Psoriasis Clinical Research Center, Tongji University, Shanghai, People’s Republic of ChinaCorrespondence: Yuling Shi; Qian Yu, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, People’s Republic of China, Email [email protected]; [email protected]: Psoriasis is a chronic immune-mediated inflammatory disease. Systemic therapy is usually applicable to patients who have failed topical treatment or phototherapy, but the value of early systemic therapy remains unclear.Purpose: This study aimed to evaluate the impact of disease duration on the clinical efficacy and patients reported outcomes in moderate to severe psoriasis patients treated with systemic agents.Methods: Our research was based on the SPEECH, an observational, prospective, multicenter registry. Adult patients with moderate to severe psoriasis receiving systemic therapy (including biologics, methotrexate or acitretin) were divided into groups based on disease duration: < 2 years, 2~10 years, and ≥ 10 years. The clinical efficacy was assessed using PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area), PGA (Physician Global Assessment). The Dermatology Life Quality Index (DLQI), PtGA (Patient Global Assessment) and the Hospital Anxiety and Depression Scale (HADS) were used to assess the patients reported outcomes. The treatment outcomes were analyzed at 3 months and 6 months. Using multiple logistic regression to analyze the differences between patients with different disease duration, and conducting subgroup analysis and sensitivity analysis to test the robustness of the research results.Results: A total of 1908 patients who met the criteria were included in the analysis. After 3 months of treatment, the PASI75 response rates for the three groups of patients (< 2 years, 2– 10 years, and ≥ 10 years) were 55%, 55% and 60%, respectively all p value > 0.05. No significant differences were observed among the three groups in the rates of achieving BSA < 1/3, PGA 0/1, DLQI 0/1, PtGA 0/1, HADS-A = 0, and HADS-D = 0. Notably, these outcomes still showed no significant differences at 6 months. Subgroup and sensitivity analyses also yielded consistent results.Conclusion: Disease duration does not significantly affect clinical efficacy or patients reported outcomes in patients with moderate-to-severe psoriasis receiving systemic therapy. These results indicate that early systemic therapy does not improve treatment outcomes in real clinical settings, thereby supporting the continued efficacy of step-up treatment strategy and providing novel insights into clinical practice management.Keywords: psoriasis, disease duration, systemic therapy, clinical efficacy, patients reported outcomes